Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| FASTENAL COFAST · Entity 3012 | Executive VP-Human Resources | January 02, 2026 | January 06, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
FASTENAL CO
Report date January 02, 2026 · Filed January 06, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Employee Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $41.00 · Expires 2035-12-31 | Direct | 17,560 |
Reported balance
After 2026-01-02 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2026-01-02 · Grant · Acquired 17,560 · Balance 17,560 F1: The option will fully vest and become exercisable over a period of four years, with 25% vesting and becoming exercisable each year following the grant date. |
Filing footnotes · ownership attribution and instrument terms
F1: The option will fully vest and become exercisable over a period of four years, with 25% vesting and becoming exercisable each year following the grant date.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| January 02, 2026 Filed Jan 6, 2026 20:18 UTC | FASTENAL CO FAST · Entity 3012 | GrantEmployee Stock Option (Right to Buy) · Derivative | 17,560 | $0.00 Strike: $41.00 | $0.00 |
DisclosureSEC source: 0001967942-26-000004 · wk-form4_1767730710.xml · derivative · entry 1 Oas Noelle Joan · CIK 0001967942 · Executive VP-Human Resources 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 17,560 Underlying: Common Stock · 17,560 shares Expires 2035-12-31 F1 · derivative.exercise_date: The option will fully vest and become exercisable over a period of four years, with 25% vesting and becoming exercisable each year following the grant date. Read SEC document |
| January 02, 2025 Filed Jan 6, 2025 18:09 UTC | FASTENAL CO FAST · Entity 3012 | GrantEmployee Stock Option (Right to Buy) · Derivative | 7,812 | $0.00 Strike: $72.00 | $0.00 |
DisclosureSEC source: 0000815556-25-000044 · wk-form4_1736186963.xml · derivative · entry 1 Oas Noelle Joan · CIK 0001967942 · Executive VP-Human Resources 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 7,812 Underlying: Common Stock · 7,812 shares Expires 2034-12-31 F1 · derivative.exercise_date: The option will fully vest and become exercisable over a period of five years, with 20% vesting and becoming exercisable each year following the grant date. Read SEC document |
| January 02, 2024 Filed Jan 4, 2024 16:58 UTC | FASTENAL CO FAST · Entity 3012 | GrantEmployee Stock Option (Right to Buy) · Derivative | 27,343 | $0.00 Strike: $64.00 | $0.00 |
DisclosureSEC source: 0001415889-24-000506 · form4-01042024_040139.xml · derivative · entry 1 Oas Noelle Joan · CIK 0001967942 · EXECUTIVE VP-HUMAN RESOURCES 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 27,343 Underlying: Common Stock · 27,343 shares Expires 2033-12-31 F1 · derivative.exercise_date: The option will fully vest and become exercisable over a period of five years, with 20% vesting and becoming exercisable each year following the grant date. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.